Basal subtype breast carcinomas express EGFR and might be candidates for targeted therapy
This article has no abstract so we have provided the first paragraph of the full text.
The recent discovery that the different types of breast carcinoma have distinctive gene expression signatures has enabled tumor subtypes to be easily identified by immunohistochemical profiling techniques. Breast carcinoma subtypes are associated with different clinical outcomes, and targeted therapies might be appropriate in some cases. Here, Siziopikou and Cobleigh suggest that the basal subtype of breast carcinomas might be a candidate for therapies targeted against EGFR.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
BRCA1?sowing the seeds crooked in the furrowNature Genetics News and Views (01 Jan 2008)